Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris
Recruiting
Early Phase 1
Interventional Study
Post Inflammtory Erythema
Acne Vulgaris
Erythema
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 12 and older
- Sex
- Any
- Trial phase
- Early Phase 1
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 60 (estimated)
- Sponsor
- Pham Ngoc Thach University of Medicine · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Post-inflammatory erythema (PIE) is a common sequela of acne vulgaris, characterized by persistent erythematous macules resulting from superficial vascular dilation. Current treatment options include energy-based devices such as intense pulsed light (IPL); however, these modalities may be costly and require specialized equipment.
Timolol, a non-selective beta-adrenergic receptor blocker, has demo…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria: Participants must meet all of the following criteria:
* Age ≥ 12 years with a history of acne vulgaris.
* Clinically diagnosed with post-inflammatory erythema (PIE) secondary to acne vulgaris.
* Willing and able to provide informed consent (or assent with parental/guardian conse…
Contacts